iQIYI (NASDAQ:IQ) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.36) by 30.56 percent. This is a 55.36 percent increase over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.18 billion by 1.69 percent. This is a 9.09 percent increase over sales of $1.10 billion the same period last year.
Verve’s Stock Price Could Continue To Rise Through Clinical Progress – Despite Worries About “DeeperPocketed” Competition
Credit Suisse has initiated coverage on Verve Therapeutics Inc (NASDAQ:VERV) with a Neutral rating and a $48 target price. Its lead assets…
